塔西利司(GDC-032)是羅氏公司開發(fā)的一種實(shí)驗(yàn)性癌癥藥物。它是一種靶向磷脂酰肌醇3-激酶亞型PIK3CA的小分子抑制劑。
Ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanoate
9-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
5-Bromo-2-(1H-imidazol-2-yl)phenol
9-Bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine
9-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylic acid
4-Bromo-2-fluoro-N-hydroxybenzimidamide
Ethyl 2-(4-bromo-1H-pyrazol-1-yl)-2-methylpropanoate
2-(4-(2-(1-Isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid
